Core Viewpoint - The stock of Longshen Rongfa has shown a mixed performance with a year-to-date increase of 22.06%, but a recent decline over the past 60 days, indicating potential volatility in the market [1]. Financial Performance - For the period from January to September 2025, Longshen Rongfa reported a revenue of 647 million yuan, representing a year-on-year decrease of 19.71%. However, the net profit attributable to shareholders increased by 9.13% to 27.03 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 42.64 million yuan, with 24.27 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, the number of shareholders for Longshen Rongfa decreased by 2.52% to 27,100, while the average number of tradable shares per shareholder increased by 2.59% to 11,147 shares [2]. - The fifth largest circulating shareholder is Huatai-PB Asset Management's Zhongzheng Traditional Chinese Medicine ETF, which holds 1.33 million shares, an increase of 351,800 shares compared to the previous period [3]. Market Activity - On November 11, the stock price of Longshen Rongfa rose by 2.13% to 10.57 yuan per share, with a trading volume of 65.20 million yuan and a turnover rate of 2.07%. The total market capitalization stands at 3.206 billion yuan [1]. - The net inflow of main funds was 2.31 million yuan, with significant buying activity from large orders [1]. Business Overview - Longshen Rongfa, established on June 3, 2002, and listed on September 13, 2016, primarily engages in the production and sales of traditional Chinese medicine, with 86.53% of its revenue derived from pharmaceutical sales [1]. - The company operates within the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [1].
陇神戎发涨2.13%，成交额6520.46万元，主力资金净流入231.41万元